# Myeloid-derived PD-L1 characterizes spatially organized immune architecture in colorectal cancer

**Authors:** Qian Wu, Stephanie Tissot, Allyson Peddle, Ke Yin, Xavier Sagaert, Gert De Hertogh, Benyagoub Abdelkader, Ting Pu, Filip Van Herpe, André D’Hoore, Sylvie Rusakiewicz, Sara Verbandt, Sabine Tejpar, Gertjan Rasschaert

PMC · DOI: 10.3389/fimmu.2026.1763068 · Frontiers in Immunology · 2026-02-06

## TL;DR

This study explores how immune cells are arranged in colorectal cancer, finding that PD-L1 on myeloid cells and specific immune cell patterns at the tumor edge may help predict immunotherapy response.

## Contribution

The study reveals spatially organized immune architecture in CRC, emphasizing PD-L1 on myeloid cells and immune cell interactions at the tumor invasive margin.

## Key findings

- PD-L1 expression is mainly on stromal and immune cells, especially CD163+ macrophages at the tumor invasive margin.
- High CD8/PD-L1 infiltration is linked to increased densities of immune cells like CD20+, CD8+, and NK cells at the invasive margin.
- CD4+Foxp3+ regulatory cells correlate with PD-1+ and CD8+PD-1+ cells at the invasive margin but not in the tumor center.

## Abstract

The tumor immune microenvironment (TIME) is highly heterogeneous and strongly influences immunotherapy outcomes and patient prognosis in colorectal cancer (CRC). In this exploratory study, we used three multiplex immunofluorescence (mIF) assays to characterize the spatial immune microenvironment associated with high CD8/PD-L1 infiltration.

Three mIF assays quantified the cell densities (cells/mm2) of CD3, CD8, PD-L1, PD-1, CD163, CD56, CD4, Foxp3, Granzyme B (GrzB), CD20, CD11c, CD15, Ki67, and cytokeratin (CK) in the invasive margin (IM) and tumor center (TC) using digital image analysis. Patients were stratified based on CD8/PD-L1 densities and their proximity (cut-off: 20μm) in IM and TC. Immune microenvironment composition was compared between high and low infiltration groups across IM and TC.

PD-L1 expression was predominantly driven from stromal and immune cells with enrichment at IM versus TC, particularly on CD163+ macrophages. Patients with high CD8/PD-L1 infiltration demonstrated significantly increased densities of CD20+, CD3+, PD-1+, CD8+PD-1+, and CD56+ natural killer (NK) cells across tumor tissue, specifically enriched at IM. CD4+Foxp3+ regulatory cells positively correlate with PD-1+, CD8+PD-1+, and CD56+ cells in IM but not TC.

This exploratory mIF analysis identifies PD-L1 expression predominantly on stromal and immune cells, enriched in IM, particularly on CD163+ macrophages. High CD8/PD-L1 tumors display spatially organized IM-specific immune niches featuring coordinated effector-regulatory interactions. Comprehensive spatial profiling of IM-enriched populations, including B cells, CD163+ macrophages, regulatory T cells, and NK cells alongside CD8/PD-L1, may refine patient stratification for immunotherapy in CRC.

## Linked entities

- **Genes:** CD8A (CD8 subunit alpha) [NCBI Gene 925], CD274 (CD274 molecule) [NCBI Gene 29126], PDCD1 (programmed cell death 1) [NCBI Gene 5133], cd.3 (Cd.3 conserved hypothetical protein) [NCBI Gene 1258599], CD163 (CD163 molecule) [NCBI Gene 9332], NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684], CD4 (CD4 molecule) [NCBI Gene 920], FOXP3 (forkhead box P3) [NCBI Gene 50943], MS4A1 (membrane spanning 4-domains A1) [NCBI Gene 931], ITGAX (integrin subunit alpha X) [NCBI Gene 3687], FUT4 (fucosyltransferase 4) [NCBI Gene 2526], Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345], krt12.4.S (Keratin 12, gene 4 S homeolog) [NCBI Gene 379143]
- **Proteins:** CD274 (CD274 molecule), PDCD1 (programmed cell death 1)
- **Diseases:** colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** CD40 (CD40 molecule) [NCBI Gene 397395] {aka TNFRSF5}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, SLA-DRB1 (MHC class II histocompatibility antigen SLA-DRB1) [NCBI Gene 100153386] {aka DRB1, LA-DRB-c, LA-DRB-d, SLA-DRB, SLADRB}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, CSF1R (colony stimulating factor 1 receptor) [NCBI Gene 100517086], CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, FOXP3 (forkhead box P3) [NCBI Gene 444998], CD4 (CD4 molecule) [NCBI Gene 404704], TENM1 (teneurin transmembrane protein 1) [NCBI Gene 10178] {aka ODZ1, ODZ3, TEN-M1, TEN1, TNM, TNM1}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, CD74 (CD74 molecule) [NCBI Gene 396660], CD3E (CD3 epsilon subunit of T-cell receptor complex) [NCBI Gene 397455] {aka CD3}, CD274 (CD274 molecule) [NCBI Gene 574058] {aka PDL1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, ITGAX (integrin subunit alpha X) [NCBI Gene 3687] {aka CD11C, SLEB6}, GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, FUT4 (fucosyltransferase 4) [NCBI Gene 2526] {aka CD15, ELFT, FCT3A, FUC-TIV, FUTIV, LeX}
- **Diseases:** MSI-H tumors (MESH:D009369), lung (MESH:D008171), epithelial tumor (MESH:D002277), NSCLC (MESH:D002289), MSS (MESH:D013132), metastases (MESH:D009362), epithelial (MESH:D009375), CRC (MESH:D015179), IM (MESH:D010437), immune dysfunction (MESH:D007154), tumor-node-metastasis (MESH:D008207), H (MESH:D000848)
- **Chemicals:** paraffin (MESH:D010232), xylene (MESH:D014992), water (MESH:D014867), ethanol (MESH:D000431), H&amp;E (MESH:D006371), Hematoxylin &amp;Eosin (-), Hematoxylin (MESH:D006416), eosin (MESH:D004801), DAPI (MESH:C007293), Formalin (MESH:D005557)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12920468/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12920468/full.md

## References

48 references — full list in the complete paper: https://tomesphere.com/paper/PMC12920468/full.md

---
Source: https://tomesphere.com/paper/PMC12920468